Characteristics and outcomes of the Italian subpopulation enrolled in the observational, multicenter hypopituitary control and complications study (HypoCCS)

Gianluca Aimaretti; Diego Ferone; Maria Rosaria Ambrosio; Paolo Beck-Peccoz; Salvatore Cannavo; Anna Maria Colao; Marco Losa; Beverly Festin Martinez; Paolo Marchi; Alessandra Vottero

doi:10.1530/endoabs.32.P907

P907

Prev Next

Section Contents Cite

Endocrine Abstracts (2013) 32 P907 | DOI: 10.1530/endoabs.32.P907

ECE2013 Poster Presentations Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) (127 abstracts)

Characteristics and outcomes of the Italian subpopulation enrolled in the observational, multicenter hypopituitary control and complications study (HypoCCS)

Gianluca Aimaretti ¹ , Diego Ferone ² , Maria Rosaria Ambrosio ³ , Paolo Beck-Peccoz ⁴ , Salvatore Cannavò ⁵ , Anna Maria Colao ⁶ , Marco Losa ⁷ , Beverly Festin Martinez ⁸ , Paolo Marchi ⁹ & Alessandra Vottero ⁹

Views

Author affiliations View ePoster Download ePoster

¹Department of Translational Medicine, University of the Eastern Piedmont, Novara, Italy; ²Endocrinology Unit, Department of Internal Medicine and Medical Specialties and Center of Excelence for Biomedical Research, IRCCS AOU San Martino-IST, Genoa, Italy; ³Department of Medical sciences, University of Ferrara, Ferrara, Italy; ⁴Department of MedicalSciences, Fondazione Policlinico IRCCS, Milan, Italy; ⁵Department of Clinical and Experimental Medicine – Endocrinology, University of Messina, Messina, Italy; ⁶University Federico II of Naples, Naples, Italy; ⁷Department of Neurosurgery, IRCCS San Raffaele, Università Vita-Salute, Milan, Italy; ⁸Eli Lilly & Co, Indianapolis, USA; ⁹Medical department, Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy.

Aim: To describe characteristics and outcomes of Italian patients with hypopituitarism participating in HypoCCS.

Methods: Study population was stratified by max GH peak (mGHp) and BMI. Baseline variables included demographic characteristics, type of deficit, smoking habits; variables analyzed over time included weight, Framingham cardiovascular disease (CVD) risk, lipids, GH dose.

Results: Italian subpopulation included 342 patients with mGHp ≤33 (group A); 345 with 33<mGHp≤66 (group B); and 337 with mGHpk >66 percentile (group C) with mean age (years (S.D.)) of 44.2 (16.2), 44. 6 (16.0), 42.6 (15.1), respectively, and adult onset GHD ((%): 75.8, 77.1 and 78.4% respectively). GHD was diagnosed mainly with GHRH+Arginine test (roughly 66% of diagnoses) and percentage of multiple pituitary hormone deficits was higher (P<0.001) in subgroup A (92.7) than in B (85.2) or C (69.5). Patients were equally distributed across normal-, under- and over-weight with average BMI of 28. No differences were detected in smoking habits or in Framingham CVD risk at baseline. More patients in group A than in B or C had hyperlipidemia (n (%): 92 (35.1), 86 (31.1), 69 (24.7) respectively; P=0.029). Mean GH dose at baseline was significantly lower in group A than in B and C (dose/kg (S.D.): 311.0 (162.5), 356.3 (217.9), 391.7 (323.1); P=0.0009) and with a longer treatment duration (years (S.D.): 7.2 (9.2), 5.5 (8.2), 5.0 (7.6); P=0.0014). Analyses over time showed group differences only at certain single time-points. Overall, no significant differences in treatment emergent adverse events (TEAEs) were detected across subgroups, while among the serious TEAEs, only ‘infections and infestations’ were significantly different (n (%): 6 (1.8), 5 (1.5), 0 (0.00); P=0.0406).

Conclusions: Italian patients with mGHp <33 percentile had the worst lipid profile and were given the lower GH treatment dose. The highest percentage of multiple deficits in this group suggests the more severe GHD.